Atrial fibrillation's structural progression can be meaningfully slowed or reversed through targeted interventions: alcohol restriction to ≤3 drinks/week reduces arrhythmia recurrence; a 10% body weight reduction reverses epicardial adipose tissue-driven atrial fibrosis; strict blood pressure control prevents irreversible remodeling; SGLT2 inhibitors and GLP-1 receptor agonists confer electrophysiological and structural benefits independent of glycemic control; and CPAP therapy for obstructive sleep apnea improves both medical and catheter ablation success rates. Moderate caffeine intake, notably, carries no elevated AF risk.
What makes this synthesis clinically important is the convergence of evidence around AF as a modifiable metabolic and structural disease, not merely an electrical one. For decades, cardiology defaulted to rhythm control and anticoagulation as endpoints. The emerging paradigm — that upstream risk factor management can alter the myocardial substrate itself — is substantively supported by the LEGACY trial data on weight loss, RACE 3 trial on targeted therapy, and accumulating SGLT2 inhibitor evidence. The GLP-1 agonist inclusion is particularly timely given the rapid adoption of semaglutide and tirzepatide in obesity management.
Limitations are real: this is a review, not novel primary research, making causal inference dependent on the quality of cited trials, many of which are moderate-sized. Applicability varies by AF stage and comorbidity burden. Still, for practicing clinicians and informed adults managing cardiovascular risk, the actionable threshold here is unusually low — weight, blood pressure, alcohol, and sleep apnea are all addressable today.
